GGrantIndex
← Leaderboards

Drew Weissman

University Of Pennsylvania

Google Scholar ↗PubMed ↗ORCID ↗
$21,263,557
Attributed
$28,720,990
Total exposure
19
Grants
13
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $8.1M · FY2005–25
$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$33,310,852 · 20

By mechanism

R01$21,282,816 · 9
U19$5,890,979 · 5
UM1$3,568,644 · 1
R33$1,433,450 · 1
R21$1,077,213 · 3
P51$57,750 · 1

Top collaborators

Most similar at University Of Pennsylvania

Same institution · by research overlap

Others in their field

Top investigators on “Cells”

Research focus

CellsMediatingMessenger RnaVaccinesProteinsInfectionAntigensIn VivoVaccine DevelopmentImmune ResponseBaseResponseSurfaceImmuneSiteDesignNovel StrategiesGrantModificationAntibodiesNanoparticleProductionTissuesLipids

Grant awards (56)

Individualized HIV Curative Combination Strategy against Persistent HIV on ART$3,568,644
UM1 · FY2025 · AI
Immune repertoire remodeling following B cell-targeted CAR T cells for induction of renal allograft tolerance in non-human primates$1,648,086
R01 · FY2025 · AI
mVACS--mRNA Vaccines for C. difficile Suppression$1,529,954
U19 · FY2025 · AI
Cardiac delivery of RNA to treat contractile disorder$796,655
R01 · FY2025 · HL
Project 1: Neutralizing and decolonizing Clostridioides difficile using mRNA vaccines$254,993
U19 · FY2025 · AI · contact PI
Core A: Administrative$254,993
U19 · FY2025 · AI · contact PI
mVACS--mRNA Vaccines for C. difficile Suppression$1,529,954
U19 · FY2024 · AI
Cardiac delivery of RNA to treat contractile disorder$793,828
R01 · FY2024 · HL
Vascular Targeting of Nanocarriers for RNA$767,434
R01 · FY2024 · HL
Project 1: Neutralizing and decolonizing Clostridioides difficile using mRNA vaccines$311,038
U19 · FY2024 · AI · contact PI
Core A: Administrative$91,182
U19 · FY2024 · AI · contact PI
mVACS--mRNA Vaccines for C. difficile Suppression$1,529,954
U19 · FY2023 · AI
Vascular Targeting of Nanocarriers for RNA$792,842
R01 · FY2023 · HL
Project 1: Neutralizing and decolonizing Clostridioides difficile using mRNA vaccines$301,171
U19 · FY2023 · AI · contact PI
Core A: Administrative$87,740
U19 · FY2023 · AI · contact PI
Vascular Targeting of Nanocarriers for RNA$801,819
R01 · FY2022 · HL
Vascular Targeting of Nanocarriers for RNA$726,234
R01 · FY2021 · HL
In Vivo RNA-Mediated Gene Editing of Hemophilia A$636,665
R01 · FY2020 · HL · contact PI
Nucleoside modified mRNA based HIV vaccine$836,210
R01 · FY2019 · AI · contact PI
In Vivo RNA-Mediated Gene Editing of Hemophilia A$679,764
R01 · FY2019 · HL · contact PI
Nucleoside modified mRNA based HIV vaccine$839,218
R01 · FY2018 · AI · contact PI
In Vivo RNA-Mediated Gene Editing of Hemophilia A$730,924
R01 · FY2018 · HL · contact PI
Nucleoside modified mRNA based HIV vaccine$842,141
R01 · FY2017 · AI · contact PI
In Vivo RNA-Mediated Gene Editing of Hemophilia A$761,424
R01 · FY2017 · HL · contact PI
Nucleoside modified mRNA based HIV vaccine$859,974
R01 · FY2016 · AI · contact PI
Gp340 and syndecan inhibition based microbicide for HIV$488,224
R33 · FY2014 · AI · contact PI
Optimizing HIV Env immuogens for T and B cell vaccine responses$517,685
R01 · FY2013 · AI · contact PI
Gp340 and syndecan inhibition based microbicide for HIV$450,725
R33 · FY2013 · AI · contact PI
Optimizing HIV Env immuogens for T and B cell vaccine responses$551,934
R01 · FY2012 · AI · contact PI
Gp340 and syndecan inhibition based microbicide for HIV$494,501
R33 · FY2012 · AI · contact PI
Optimizing HIV Env immuogens for T and B cell vaccine responses$654,103
R01 · FY2011 · AI · contact PI
RNA delivery for dendritic cell HIV antigen presentation$385,914
R01 · FY2011 · AI · contact PI
IMMUNIZATION ACTIVATES TRANSIENT SIV VIRAL REPLICATION$57,750
P51 · FY2011 · RR · contact PI
Optimizing HIV Env immuogens for T and B cell vaccine responses$587,041
R01 · FY2010 · AI · contact PI
RNA delivery for dendritic cell HIV antigen presentation$389,813
R01 · FY2010 · AI · contact PI
Gp340 and syndecan inhibition based microbicide for HIV$217,318
R21 · FY2010 · AI · contact PI
RNA delivery for dendritic cell HIV antigen presentation$393,750
R01 · FY2009 · AI · contact PI
Gp340 and syndecan inhibition based microbicide for HIV$219,338
R21 · FY2009 · AI · contact PI
Oral Delivery of RNA Encoded Antigen$183,094
R21 · FY2009 · DE · contact PI
RNA delivery for dendritic cell HIV antigen presentation$393,750
R01 · FY2008 · AI · contact PI
Role of gp-340 in HIV Infection and Transmission$368,577
R01 · FY2008 · AI · contact PI
Oral Delivery of RNA Encoded Antigen$219,713
R21 · FY2008 · DE · contact PI
Role of gp-340 in HIV Infection and Transmission$375,716
R01 · FY2007 · AI · contact PI
RNA DELIVERY FOR DENDRITIC CELL HIV ANTIGEN PREVENTION$74,960
R01 · FY2007 · AI · contact PI
Role of gp-340 in HIV Infection and Transmission$386,938
R01 · FY2006 · AI · contact PI
RNA DELIVERY FOR DENDRITIC CELL HIV ANTIGEN PREVENTION$386,938
R01 · FY2006 · AI · contact PI
RNA DELIVERY FOR DENDRITIC CELL HIV ANTIGEN PREVENTION$396,250
R01 · FY2005 · AI
Role of gp-340 in HIV Infection and Transmission$396,250
R01 · FY2005 · AI
RNA DELIVERY FOR DENDRITIC CELL HIV ANTIGEN PREVENTION$396,250
R01 · FY2004 · AI
Role of gp-340 in HIV Infection and Transmission$396,250
R01 · FY2004 · AI
RNA DELIVERY FOR DENDRITIC CELL HIV ANTIGEN PREVENTION$396,250
R01 · FY2003 · AI
RNA DELIVERY FOR DENDRITIC CELL HIV ANTIGEN PREVENTION$396,250
R01 · FY2002 · AI
ANTIGEN SPECIFIC ACTIVATION AND HIV REPLICATION$308,039
R01 · FY2002 · HL
ANTIGEN SPECIFIC ACTIVATION AND HIV REPLICATION$308,329
R01 · FY2001 · HL
ANTIGEN SPECIFIC ACTIVATION AND HIV REPLICATION$308,611
R01 · FY2000 · HL
RNA DELIVERY FOR DENDRITIC CELL HIV ANTIGEN PRESENTATION$237,750
R21 · FY2000 · AI